Literature DB >> 20563248

Invasive glioblastoma cells acquire stemness and increased Akt activation.

Jennifer R Molina1, Yuho Hayashi, Clifton Stephens, Maria-Magdalena Georgescu.   

Abstract

Glioblastoma multiforme (GBM) is the most frequent and most aggressive brain tumor in adults. The dismal prognosis is due to postsurgery recurrences arising from escaped invasive tumor cells. The signaling pathways activated in invasive cells are under investigation, and models are currently designed in search for therapeutic targets. We developed here an in vivo model of human invasive GBM in mouse brain from a GBM cell line with moderate tumorigenicity that allowed simultaneous primary tumor growth and dispersal of tumor cells in the brain parenchyma. This strategy allowed for the first time the isolation and characterization of matched sets of tumor mass (Core) and invasive (Inv) cells. Both cell populations, but more markedly Inv cells, acquired stem cell markers, neurosphere renewal ability, and resistance to rapamycin-induced apoptosis relative to parental cells. The comparative phenotypic analysis between Inv and Core cells showed significantly increased tumorigenicity in vivo and increased invasion with decreased proliferation in vitro for Inv cells. Examination of a large array of signaling pathways revealed extracellular signal-regulated kinase (Erk) down-modulation and Akt activation in Inv cells and an opposite profile in Core cells. Akt activation correlated with the increased tumorigenicity, stemness, and invasiveness, whereas Erk activation correlated with the proliferation of the cells. These results underscore complementary roles of the Erk and Akt pathways for GBM proliferation and dispersal and raise important implications for a concurrent inhibitory therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20563248      PMCID: PMC2887086          DOI: 10.1593/neo.10126

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  38 in total

1.  A perivascular niche for brain tumor stem cells.

Authors:  Christopher Calabrese; Helen Poppleton; Mehmet Kocak; Twala L Hogg; Christine Fuller; Blair Hamner; Eun Young Oh; M Waleed Gaber; David Finklestein; Meredith Allen; Adrian Frank; Ildar T Bayazitov; Stanislav S Zakharenko; Amar Gajjar; Andrew Davidoff; Richard J Gilbertson
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

2.  Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 organizes ERM proteins at the apical membrane of polarized epithelia.

Authors:  Fabiana C Morales; Yoko Takahashi; Erica L Kreimann; Maria-Magdalena Georgescu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-10       Impact factor: 11.205

Review 3.  Restraining PI3K: mTOR signalling goes back to the membrane.

Authors:  Laura S Harrington; Greg M Findlay; Richard F Lamb
Journal:  Trends Biochem Sci       Date:  2005-01       Impact factor: 13.807

4.  Angiogenesis-independent tumor growth mediated by stem-like cancer cells.

Authors:  Per Ø Sakariassen; Lars Prestegarden; Jian Wang; Kai-Ove Skaftnesmo; Rupavathana Mahesparan; Carla Molthoff; Peter Sminia; Eirik Sundlisaeter; Anjan Misra; Berit Bølge Tysnes; Martha Chekenya; Hans Peters; Gabriel Lende; Karl Henning Kalland; Anne M Øyan; Kjell Petersen; Inge Jonassen; Albert van der Kogel; Burt G Feuerstein; A Jorge A Terzis; Rolf Bjerkvig; Per Øyvind Enger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

5.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

Authors:  Jeongwu Lee; Svetlana Kotliarova; Yuri Kotliarov; Aiguo Li; Qin Su; Nicholas M Donin; Sandra Pastorino; Benjamin W Purow; Neil Christopher; Wei Zhang; John K Park; Howard A Fine
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

6.  PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling.

Authors:  Yoko Takahashi; Fabiana C Morales; Erica L Kreimann; Maria-Magdalena Georgescu
Journal:  EMBO J       Date:  2006-02-02       Impact factor: 11.598

7.  PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms.

Authors:  John Brognard; Emma Sierecki; Tianyan Gao; Alexandra C Newton
Journal:  Mol Cell       Date:  2007-03-23       Impact factor: 17.970

Review 8.  Genetic pathways to primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

Review 9.  Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Authors:  Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

Review 10.  Signaling pathways in cancer and embryonic stem cells.

Authors:  Oliver Dreesen; Ali H Brivanlou
Journal:  Stem Cell Rev       Date:  2007-01       Impact factor: 6.692

View more
  90 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Three-dimensional cell culturing by magnetic levitation.

Authors:  William L Haisler; David M Timm; Jacob A Gage; Hubert Tseng; T C Killian; Glauco R Souza
Journal:  Nat Protoc       Date:  2013-09-12       Impact factor: 13.491

Review 3.  Glioblastoma cancer stem cells: Biomarker and therapeutic advances.

Authors:  Kelli B Pointer; Paul A Clark; Michael Zorniak; Bahauddeen M Alrfaei; John S Kuo
Journal:  Neurochem Int       Date:  2014-03-19       Impact factor: 3.921

Review 4.  Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.

Authors:  Sagar Agarwal; Ramola Sane; Rajneet Oberoi; John R Ohlfest; William F Elmquist
Journal:  Expert Rev Mol Med       Date:  2011-05-13       Impact factor: 5.600

5.  Atypical cell populations associated with acquired resistance to cytostatics and cancer stem cell features: the role of mitochondria in nuclear encapsulation.

Authors:  David Díaz-Carballo; Sebastian Gustmann; Holger Jastrow; Ali Haydar Acikelli; Philip Dammann; Jacqueline Klein; Ulrike Dembinski; Walter Bardenheuer; Sascha Malak; Marcos J Araúzo-Bravo; Beate Schultheis; Constanze Aldinger; Dirk Strumberg
Journal:  DNA Cell Biol       Date:  2014-08-15       Impact factor: 3.311

6.  Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.

Authors:  Elisa Carra; Federica Barbieri; Daniela Marubbi; Alessandra Pattarozzi; Roberto E Favoni; Tullio Florio; Antonio Daga
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

Review 7.  Using space-based investigations to inform cancer research on Earth.

Authors:  Jeanne L Becker; Glauco R Souza
Journal:  Nat Rev Cancer       Date:  2013-04-12       Impact factor: 60.716

8.  MicroRNA-542-3p Suppresses Tumor Cell Invasion via Targeting AKT Pathway in Human Astrocytoma.

Authors:  Junchao Cai; JingJing Zhao; Nu Zhang; Xiaonan Xu; Rong Li; Yang Yi; Lishan Fang; Le Zhang; Mengfeng Li; Jueheng Wu; Heng Zhang
Journal:  J Biol Chem       Date:  2015-08-18       Impact factor: 5.157

9.  Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells.

Authors:  Dah-Yuu Lu; Wei-Lan Yeh; Ssu-Ming Huang; Chih-Hsin Tang; Hsiao-Yun Lin; Shao-Jiun Chou
Journal:  Neuro Oncol       Date:  2012-10-16       Impact factor: 12.300

10.  Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.

Authors:  Xiangyu Liu; Kangjian Sun; Handong Wang; Yuyuan Dai
Journal:  Cell Mol Neurobiol       Date:  2016-03-14       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.